Why Choose Us?
Cell and Gene Therapies (CGT) represent a transformative shift in cancer and autoimmune disease treatment by addressing the root causes rather than merely managing symptoms. These therapies work by engineering immune cells or modifying their genes to target and eliminate harmful cells or reset immune responses, allowing for precision medicine that adapts to each patient’s specific needs. This approach stands in stark contrast to traditional therapies, which often involve generalized immune suppression or toxic chemotherapy, carrying significant side effects and a limited impact on disease durability.
The Market is Growing
The Cell and Gene Therapies (CGT) Industry with targeted genome engineering is expected to grow with a compound annual growth rate of 19.0% until 2027. With the recent uprise in FDA-approved cell therapies, quite a few R&D deals were signed in 2023 for platforms and discovery-stage ventures.
Full Circles Highlights
4 Publications
7 Patents
Scalable Munufacture
LNP Delivery
With a growing market space, CGT industry has a lot of untapped potential to provide cures and therapies for chronic diseases. Full Circles stands out from the competitive landscape, enabling higher payload delivery capabilities alongside improved efficiency. This contributes to the creation of a modality agnostic platform that helps precise engineering of cells and safer integration of cargo into the genome.
Agnostic Platform
Adaptable to Cell type, Locus, Payload, and Nuclease Editors
Expanded Payloads
From a Few Hundred to 20 kb
with High Fidelity
Precision Engineering
CRISPR with Non-Viral
Delivery
Safe Integration
Minimal Cytotoxicity and
Cellular Response
More Reach
Flexible with ex vivo or
in vivo Delivery
Cost & Time Effective
Scaled Manufacture and Accelerate Cell Engineering
Partner with us
Let’s join hands to achieve a world without genetic disorders.
We are looking to form strategic partnerships for cell engineering workflows and cell line development alongside rapid manufacturing of biologics, including CAR T cells and hematopoietic stem cells. Feel free to explore our current pipelines in development or reach out to talk with us about a new possibility. We can also license our technology to support your workflows.